CDCA2 Promotes HCC Cells Development via AKT-mTOR Pathway.

Area of Science:

• Oncology
• Molecular Biology

Background:

• Hepatocellular carcinoma (HCC) is an aggressive malignancy with poor patient prognosis.
• Cell division cycle associated 2 (CDCA2) is overexpressed in HCC and linked to patient outcomes.
• The specific role and mechanism of CDCA2 in HCC remain to be fully elucidated.

Purpose of the Study:

• To investigate the functional role of CDCA2 in HCC cells.
• To explore the underlying molecular mechanism by which CDCA2 influences HCC progression.

Main Methods:

• Gain- and loss-of-function experiments were performed on HCC cells.
• Quantitative reverse transcription-polymerase chain reaction and Western blot assessed CDCA2 mRNA and protein levels.
• Cell viability, colony formation, migration, and invasion assays evaluated malignant behaviors. Western blot also analyzed the AKT-mTOR pathway and Cyclin D1 expression.

Main Results:

• CDCA2 expression was significantly increased in HCC cell lines.
• Upregulation of CDCA2 enhanced HCC cell growth, migration, and invasion, while depletion had opposite effects.
• CDCA2 upregulation correlated with increased levels of phosphorylated AKT (p-AKT), phosphorylated mTOR (p-mTOR), and Cyclin D1, which decreased upon CDCA2 depletion.

Conclusions:

• CDCA2 significantly promotes the malignant progression of HCC cells.
• The AKT-mTOR signaling pathway is implicated in the mechanism by which CDCA2 drives HCC development.